Protherics falls deeper into loss in fiscal 2007/8
UK-based biopharmaceutical company Protherics reported an increased loss for the financial year ending March 31, 2008, partially due to increased R&D spending.
The firm recorded a fall in revenue for the year to L26.1 million ($51.2 million) versus L31.1 million in the previous financial year. This brought the company's net loss to L16.7 million vs L3.4 million year-on-year, or loss per share of L0.05 vs L0.01. Protherics attributes these results to expected increased R&D spending on its development pipeline and acquisitions made in January 2007. R&D expenditure was L19.1 million vs L14.0 million in the year before.
Loss increased despite the firm receiving a L10.0 million milestone payment from AstraZeneca for the CytoFab anti-TNF-alpha polyclonal antibody fragment, indicated to treat sepsis resulting from uncontrolled infection. Sales of the drug decreased to L2.3 million vs L12.2 million, as it entered into a Phase II trial conducted by AstraZeneca.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze